EPIMED RESEARCH

Intellectual Property Experts in Life Sciences

    • Blog
    • Home
    • Technologies Available for licensing
  • What’s patent eligible and what’s not: patent eligible subject matter comparison – China

    What’s patent eligible and what’s not: patent eligible subject matter comparison – China

    As a national strategy, China is trying to move from being a world manufacturing factory to being an innovation leader.  Since the introduction of the “Law of the People’s Republic of China on Progress of Science and Technology” in 2008, China has made staggering progress toward promoting the scientific and technological innovations, which is evidenced by…

    epimedresearch

    February 4, 2014
    Uncategorized
  • Summary of the America Invents Act

    Summary of the America Invents Act

    Repost from AIPLA: http://www.aipla.org/advocacy/congress/aia/Pages/summary.aspx Filing Reforms Examination Reforms Third Party Reforms Additional Key Reforms Other Provisions Thanks for reading. Contact us at info@epimedresearch.com

    epimedresearch

    November 15, 2013
    Uncategorized
  • Maximizing exclusivity for pharmaceutical products

    Maximizing exclusivity for pharmaceutical products

    1. The Hatch-Waxman Act The Drug Price Competition and Patent Term Restoration Act, commonly known as the “Hatch-Waxman” Act, was enacted in USA in 1984.  The Act aims to strike a balance between the drug innovators and generic manufacturers by permitting limited extensions of patent term to compensate for market time lost during the drug approval…

    epimedresearch

    October 12, 2013
    Uncategorized
  • On-sale bar to patentability could be triggered by an order to your own OME manufacturer

    On-sale bar to patentability could be triggered by an order to your own OME manufacturer

    On-sale bar is a patentability bar derived from 35 U.S.C. 102 of the U.S. Patent Law.  Under 35 U.S.C. 102(a), a person shall be entitled to a patent unless- (1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing…

    epimedresearch

    August 22, 2013
    Uncategorized
  • Patent Eligibility of Gene: isolated gene not patent eligible in US

    Patent Eligibility of Gene: isolated gene not patent eligible in US

    Well, it’s final—isolated gene is no longer patent eligible in US.  The multi-years long, contentious and emotional fight on the gene patentability climaxed with a straightforward decision from U.S. Supreme Court in Association for Molecular Pathology v. Myriad, 569 U.S.____ on June 13, 2013.  The case began with Myriad’s identification and sequencing of the two breast cancer-causing…

    epimedresearch

    June 20, 2013
    Uncategorized
  • Climbing up to the World Stage: the Third Amendment to the Chinese Patent Law

    Climbing up to the World Stage: the Third Amendment to the Chinese Patent Law

    In a showing of its desire to transform from a world’s factory into an innovation-oriented country, China recently announced the enactment of the third amendment to the Chinese Patent Law. Since adopting its original Patent Law in 1984, China has enacted two amendments, the first in 1992 and the second in 2000. The first amendment…

    epimedresearch

    September 10, 2012
    Uncategorized
  • Summary and Implication of Phillips v. AWH Corp.

    Summary and Implication of Phillips v. AWH Corp.

    Introduction On July 12, 2005 , the Federal Circuit issued its en banc decision in Phillips v. AWH Corp., addressing fundamental questions regarding patent claim construction. See Phillips v. AWH Corp., No. 03-1269, -1286 (Fed. Cir. Jul. 12, 2005 ). The decision clarifies a handful of issues central to the claim construction process, in particular, the emphasis that is to be…

    epimedresearch

    July 12, 2012
    Uncategorized
Previous Page
1 … 4 5 6

EPIMED RESEARCH

A full-service IP and FDA firm specializing in intellectual property strategy and management, technology commercialization, and FDA regulatory compliance. We help to protect and maximize the value of your most important asset.

Bellevue
Washington

Email us

Info@epimedresearch.com

LinkedIn

Copyright@2012 EpiMed LLC. All rights reserved

  • Subscribe Subscribed
    • EPIMED RESEARCH
    • Already have a WordPress.com account? Log in now.
    • EPIMED RESEARCH
    • Subscribe Subscribed
    • Sign up
    • Log in
    • Report this content
    • View site in Reader
    • Manage subscriptions
    • Collapse this bar